Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

624 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Sars-CoV2 infection in pregnant women with multiple sclerosis.
Aprea MG, Schiavetti I, Portaccio E, Ballerini C, Battaglia MA, Bergamaschi R, Brichetto G, Bunul SD, Calabrese M, Capobianco M, Cavalla P, Celani MG, Clerico M, Cocco E, Comi G, Confalonieri P, Conte A, Cordioli C, De Luca G, De Rossi N, Filippi M, Gumes H, Immovilli P, Inglese M, Karabudak R, Landi D, Lanzillo R, L'Episcopo MR, Lorefice L, Mantero V, Marangoni S, Marfia GA, Masciulli C, Milano E, Moiola L, Orlandi R, Patti F, Perini P, Pesci I, Pucci E, Puthenparampil M, Radaelli M, Salvetti M, Sartori A, Scandellari C, Sen S, Siva A, Strumia S, Teatini F, Tedeschi G, Trojano M, Tutuncu M, Vaula G, Sormani MP, Amato MP; Musc-19 Study Group. Aprea MG, et al. Among authors: sartori a. Mult Scler. 2023 Aug;29(9):1090-1098. doi: 10.1177/13524585231176174. Epub 2023 May 26. Mult Scler. 2023. PMID: 37232279 Free PMC article.
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: II: Maternal risks.
Portaccio E, Moiola L, Martinelli V, Annovazzi P, Ghezzi A, Zaffaroni M, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Solaro C, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society. Portaccio E, et al. Neurology. 2018 Mar 6;90(10):e832-e839. doi: 10.1212/WNL.0000000000005068. Epub 2018 Feb 7. Neurology. 2018. PMID: 29438041
Pregnancy decision-making in women with multiple sclerosis treated with natalizumab: I: Fetal risks.
Portaccio E, Annovazzi P, Ghezzi A, Zaffaroni M, Moiola L, Martinelli V, Lanzillo R, Brescia Morra V, Rinaldi F, Gallo P, Tortorella C, Paolicelli D, Pozzilli C, De Giglio L, Cavalla P, Cocco E, Marrosu MG, Patti F, Solaro C, Bellantonio P, Uccelli A, Laroni A, Pastò L, Giannini M, Trojano M, Comi G, Amato MP; MS Study Group of the Italian Neurological Society. Portaccio E, et al. Neurology. 2018 Mar 6;90(10):e823-e831. doi: 10.1212/WNL.0000000000005067. Epub 2018 Feb 7. Neurology. 2018. PMID: 29438046
Determinants of therapy switch in multiple sclerosis treatment-naïve patients: A real-life study.
Saccà F, Lanzillo R, Signori A, Maniscalco GT, Signoriello E, Lo Fermo S, Repice A, Annovazzi P, Baroncini D, Clerico M, Binello E, Cerqua R, Mataluni G, Bonavita S, Lavorgna L, Zarbo IR, Laroni A, Rossi S, Pareja Gutierrez L, La Gioia S, Frigeni B, Barcella V, Frau J, Cocco E, Fenu G, Torri Clerici V, Sartori A, Rasia S, Cordioli C, Di Sapio A, Pontecorvo S, Grasso R, Barrilà C, Russo CV, Esposito S, Ippolito D, Bovis F, Gallo F, Sormani MP. Saccà F, et al. Among authors: sartori a. Mult Scler. 2019 Aug;25(9):1263-1272. doi: 10.1177/1352458518790390. Epub 2018 Jul 25. Mult Scler. 2019. PMID: 30044207 Free article.
Outcomes after fingolimod to alemtuzumab treatment shift in relapsing-remitting MS patients: a multicentre cohort study.
Frau J, Saccà F, Signori A, Baroncini D, Fenu G, Annovazzi P, Capobianco M, Signoriello E, Laroni A, La Gioia S, Sartori A, Maniscalco GT, Bonavita S, Clerico M, Russo CV, Gallo A, Lapucci C, Carotenuto A, Sormani MP, Cocco E; i-MuST study group. Frau J, et al. Among authors: sartori a. J Neurol. 2019 Oct;266(10):2440-2446. doi: 10.1007/s00415-019-09424-8. Epub 2019 Jun 17. J Neurol. 2019. PMID: 31209573
Extending the Interval of Natalizumab Dosing: Is Efficacy Preserved?
Clerico M, De Mercanti SF, Signori A, Iudicello M, Cordioli C, Signoriello E, Lus G, Bonavita S, Lavorgna L, Maniscalco GT, Curti E, Lorefice L, Cocco E, Nociti V, Mirabella M, Baroncini D, Mataluni G, Landi D, Petruzzo M, Lanzillo R, Gandoglia I, Laroni A, Frangiamore R, Sartori A, Cavalla P, Costantini G, Sormani MP, Capra R. Clerico M, et al. Among authors: sartori a. Neurotherapeutics. 2020 Jan;17(1):200-207. doi: 10.1007/s13311-019-00776-7. Neurotherapeutics. 2020. PMID: 31452081 Free PMC article.
First therapy choice in newly diagnosed Multiple Sclerosis patients: A multicenter Italian study.
Maniscalco GT, Saccà F, Lanzillo R, Annovazzi P, Baroncini D, Binello E, Repice A, Perini P, Clerico M, Mataluni G, Bonavita S, La Gioia S, Gutierrez LP, Laroni A, Frau J, Cocco E, Torri Clerici V, Zarbo IR, Sartori A, Signoriello E, Rasia S, Cordioli C, Stromillo ML, Cerqua R, Pontecorvo S, Di Sapio A, Grasso R, Barone S, Lavorgna L, Barrilà C, Landi D, Russo CV, Frigeni B, Ippolito D, Turano G, Carmisciano L, Sormani MP, Signori A. Maniscalco GT, et al. Among authors: sartori a. Mult Scler Relat Disord. 2020 Jul;42:102059. doi: 10.1016/j.msard.2020.102059. Epub 2020 Mar 16. Mult Scler Relat Disord. 2020. PMID: 32208344
Cladribine vs other drugs in MS: Merging randomized trial with real-life data.
Signori A, Saccà F, Lanzillo R, Maniscalco GT, Signoriello E, Repice AM, Annovazzi P, Baroncini D, Clerico M, Binello E, Cerqua R, Mataluni G, Perini P, Bonavita S, Lavorgna L, Zarbo IR, Laroni A, Pareja-Gutierrez L, La Gioia S, Frigeni B, Barcella V, Frau J, Cocco E, Fenu G, Clerici VT, Sartori A, Rasia S, Cordioli C, Stromillo ML, Di Sapio A, Pontecorvo S, Grasso R, Barone S, Barrilà C, Russo CV, Esposito S, Ippolito D, Landi D, Visconti A, Sormani MP. Signori A, et al. Among authors: sartori a. Neurol Neuroimmunol Neuroinflamm. 2020 Aug 14;7(6):e878. doi: 10.1212/NXI.0000000000000878. Print 2020 Nov. Neurol Neuroimmunol Neuroinflamm. 2020. PMID: 32801167 Free PMC article.
Disease-Modifying Therapies and Coronavirus Disease 2019 Severity in Multiple Sclerosis.
Sormani MP, De Rossi N, Schiavetti I, Carmisciano L, Cordioli C, Moiola L, Radaelli M, Immovilli P, Capobianco M, Trojano M, Zaratin P, Tedeschi G, Comi G, Battaglia MA, Patti F, Salvetti M; Musc-19 Study Group. Sormani MP, et al. Ann Neurol. 2021 Apr;89(4):780-789. doi: 10.1002/ana.26028. Epub 2021 Feb 9. Ann Neurol. 2021. PMID: 33480077 Free PMC article.
MRI activity and extended interval of Natalizumab dosing regimen: a multicentre Italian study.
De Mercanti SF, Signori A, Cordioli C, Signoriello E, Lus G, Bonavita S, Abbadessa G, Lavorgna L, Maniscalco GT, Curti E, Lorefice L, Cocco E, Nociti V, Mirabella M, Baroncini D, Mataluni G, Landi D, Petruzzo M, Lanzillo R, Gandoglia I, Laroni A, Frangiamore R, Sartori A, Cavalla P, Costantini G, Capra R, Sormani MP, Clerico M. De Mercanti SF, et al. Among authors: sartori a. J Neurol Sci. 2021 May 15;424:117385. doi: 10.1016/j.jns.2021.117385. Epub 2021 Mar 6. J Neurol Sci. 2021. PMID: 33770708
624 results